“Our goal is no less than a wholesale shift in the standard of care for pediatric patients, moving from toxic chemotherapies that leave survivors with lifelong health challenges to effective, safe treatments that precisely target cancer without harm to the rest of the child’s body,” says Gwen Nichols, MD, LLS Chief Medical Officer.
Who are PCDC LLS?
The University of Chicago Pediatric Cancer data (PCDC) is initiating a new coactive effort of influencing big data to boost pediatric cancer precision medicine. This global initiative aims to benefit children with pediatric acute leukemia. PCDC is a precision medicine master clinical trial namely Pediatric Acute Leukemia (PedAL) from Leukemia and Lymphoma Society’s LLS.
Medical precision treatment
LLS PedAL will revolve around accelerating precision medicine for pediatric cancer patients by testing focused therapies for a deteriorated or refractory disease to appropriate clinical trials and life-sustaining treatments.
Clinical trials for appropriate decision making
The treatment will commence two trials, one within the LLS PedAL master trial and another trial will be conducted outside the PedAL for young patients suffering acute leukemia. The GEARBox will recruit doctors with multiplex trial options for best decision making amid the patients.
Coordination of cancer institutes
Additionally, other platforms of PCDC will unite Pediatric leukemia data in large masses under one roof. By assembling a universal international acute leukemia data dictionary, the PCDC will synchronize authentic and new data.
By collaborating with international leaders in pediatric cancers and legal officials PCDC targets to develop a wide orbit of clinical research. This research will modernize the role of precision medicine in pediatric cancer care.
PCDC will step forward to
- Attempt to break down of silos across sectors, scientific disciplines, institutions, and nations
- Working collaboratively with other countries
- They will research and validate basic roots and drivers of the disease
- Match patients to the most favorable therapies based on eccentric genetic information
“In the process, we will be creating the largest pediatric leukemia data set in the world.” the institute confirmed.